1. Home
  2. NNBR vs CELU Comparison

NNBR vs CELU Comparison

Compare NNBR & CELU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo NN Inc.

NNBR

NN Inc.

HOLD

Current Price

$1.25

Market Cap

63.7M

Sector

Industrials

ML Signal

HOLD

Logo Celularity Inc.

CELU

Celularity Inc.

HOLD

Current Price

$2.07

Market Cap

56.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NNBR
CELU
Founded
1980
2016
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
63.7M
56.7M
IPO Year
1994
N/A

Fundamental Metrics

Financial Performance
Metric
NNBR
CELU
Price
$1.25
$2.07
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$6.00
AVG Volume (30 Days)
273.9K
66.9K
Earning Date
10-29-2025
11-14-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$424,005,000.00
$40,578,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
$5.31
$76.00
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.20
$1.00
52 Week High
$4.67
$4.35

Technical Indicators

Market Signals
Indicator
NNBR
CELU
Relative Strength Index (RSI) 29.96 58.44
Support Level $1.22 $1.62
Resistance Level $1.46 $2.29
Average True Range (ATR) 0.12 0.14
MACD -0.00 0.06
Stochastic Oscillator 9.20 65.82

Price Performance

Historical Comparison
NNBR
CELU

About NNBR NN Inc.

NN Inc is a diversified industrial company that combines engineering and production capabilities with in-depth materials science expertise to design and manufacture high-precision solutions and components. It operates in two business segments: mobile solutions and power solutions. The mobile solutions segment involves growth in the general industrial and automotive end markets. Its power solutions segment involves growth in the electrical and aerospace and defense end markets.

About CELU Celularity Inc.

Celularity Inc is a clinical-stage biotechnology company developing off-the-shelf placental-derived allogeneic cell therapies including genetically modified and unmodified NK cells, engineered T cells including CAR-T cells, and mesenchymal-like adherent stromal cells, targeting indications across cancer, immunologic, infectious, and degenerative diseases. It manages its operations through an evaluation of three distinct business segments which include Cell Therapy, Degenerative Disease, and bio-banking. The company generates the majority of its revenue from the bio-banking segment.

Share on Social Networks: